2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 340

Hydroxychloroquine: A Potential Treatment for Osteoporosis By Osteoclast Inhibition!
Abstract Number: 1829

Hyper-Responsiveness to TLR-4 Stimulation in SLE: Association with High Levels of Serum IFN-Alpha and a Distinct Inflammatory Cytokine Profile
Abstract Number: 2792

Hyperhomocysteinemia in SLE
Abstract Number: 1935

Hypertrophic Pachymeningitis in a Population with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Study in a Single Japanese Institution
Abstract Number: 2958

Hypocomplementemic Urticarial Vasculitis (HUV) Syndrome in Two Geographically Defined Populations of Sweden
Abstract Number: 2928

Hypomethylation of an Intragenic Alternative Promoter Contributes to Impaired Treg Function in Rheumatoid Arthritis By Transcriptional Interference with Expression of the Treg-Specific Protein, Glycoprotein a Repetitions Predominant (GARP)
Abstract Number: 2563

Hypoxia Induce Slug Expression Via JAK/STAT3 Pathway in Rheumatoid Arthritis Fibroblast-like Synoviocytes
Abstract Number: 1112

Hypoxia Modulates Neutrophil Integrin Expression, Adhesion and Trans-Endothelial Migration
Abstract Number: 670

Identification and Characterization of Sjogren’s Syndrome-Associated Genetic Variants in the IL12A and DDX6-CXCR5 Loci
Abstract Number: 3242

Identification and Functional Characterization of TNIP1 Causal Variants Associated with Systemic Lupus Erythematosus
Abstract Number: 1908

Identification of a Novel Pro-Inflammatory T Cell Epitope from His-tRNA-Synthetase Associated with Interstitial Lung Disease in Anti-Jo-1 Positive Patients
Abstract Number: 2696

Identification of a Potential Commensal Immunologic Target in Enthesitis-Related Arthritis
Abstract Number: 1456

Identification of a Unique Population of B220hi B-Cells in Inflamed Lymph Nodes (Bin) As a Potential Biomarker of Arthritic Progression in the Tumor Necrosis Factor Transgenic Mouse Model of Rheumatoid Arthritis
Abstract Number: 2427

Identification of Biomarkers Using Tear Proteomics in Children with Chronic Anterior Uveitis
Abstract Number: 55

Identification of Endogenous Autoantigens Bound to Anti-Citrullinated Peptide Antibodies in Rheumatoid Arthritis: A Key Role for Citrulline Residues in Histone 4

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].